Newly revealed ShcD has been characterized as an intracellular phosphotyrosine adaptor protein belonging to the Src homology and collagen (Shc) family. These scaffolding molecules facilitate receptor-mediated signal transduction through their ability to selectively recognize and bind, via PTB and SH2 domains, to phosphorylated tyrosine residues in the cytoplasmic tails of a variety of activated receptors. A central CH1 domain couples to downstream signaling molecules including Grb2. ShcD is most similar in form to ShcA; however, unlike the latter, its expression in the mouse is localized to the brain and skeletal muscle. Consistent with this observation, we report that human ShcD is able to bind the TrkA neurotrophin receptor responsive to nerve growth factor (NGF). This interaction is similar to that of other Shc proteins in that it is strongly influenced by the TrkA Tyr 490 residue, and results in ShcD phosphorylation. Surprisingly, we find that both the PTB and SH2 domains of ShcD impact its ability to complex with TrkA, in contrast to the PTB-mediated interaction documented for traditional Shc proteins. TrkA binding analyses performed with different ShcD mutants suggest that the contributions of the PTB and SH2 domains supercede simple co-operativity, and are in fact reminiscent of auto-regulatory mechanisms. Here we report both the canonical and atypical characteristics of the ShcD / TrkA interaction, including novel proposed models of adaptor-receptor interactions.
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omplex multicellular organisms rely on signal transduction cascades to establish and maintain intricate patterns of life. The recent discovery of ShcD, a fourth member of the mammalian Src homology and collagen (Shc) repertoire, has revealed another protein in the cell's arsenal of signal transduction molecules.
Previously, three mammalian loci encoding six distinct Shc splice isoforms or start codon variants had been described, designated ShcA/Shc, ShcB/Sli, ShcC/Rai. 1 All proteins of this well-characterized family share several defining features. They function as scaffold molecules in signaling cascades, binding to select phosphorylated tyrosine (pY) residues within the cytoplasmic regions of active cell receptors. 12 Upstream targets include receptor tyrosine kinases (RTKs), G-protein coupled receptors, as well as hormone, antigen and cytokine receptors, all of which promote Shc tyrosine phosphorylation upon interaction. 12 As molecular adaptors, activated Shc can then recruit downstream binding partners to further transduce incoming signals.
The conserved modular architecture of Shc proteins includes two independent domains, an amino terminal phosphotyrosine binding (PTB) domain and carboxyterminal Src homology 2 (SH2) domain that can mediate interaction with pY residues (Figure 1) . 4 Neither domain is unique to Shc proteins; however, the inclusion of both appears to distinguish this family. 12 While PTB domainbased binding is influenced by residues N-terminal to the pY, SH2 specificity derives from amino acids downstream of the target tyrosine. 9, 12 The consensus sequence recognized by the PTB domain is an Asn-Pro-X-Tyr (NPXY) motif; 14 in contrast, binding requirements of the SH2 domain are less stringent. 4 This imparts a differential binding preference to each domain and implies a functional non-redundancy, possibly increasing the versatility of the molecule. The long isoforms of Shc A, B and C possess an amino terminal collagen homology 2 (CH2) region 12 that is proline rich and can mediate interaction with Src homology 3 (SH3) domains 4 in addition to serving as a substrate for serine kinases. 12 Likewise, a centrally-located CH1 domain includes residues that can also bind SH3 domains, although it is best known for its tyrosine consensus sequences that become phosphorylated upon Shc engagement with an activated receptor. 12 These residues in turn become targets for downstream signaling molecules including Grb2, thereby coupling Shc to pathways that include activation of Ras/Mitogen Activated Protein Kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K). 1, 5 The cellular consequences of signaling through Shc are varied; Lai and Pawson report the involvement of ShcA in determining the cytoskeletal architecture of developing cardiac tissue 6 while cell survival and proliferation are generally accepted outcomes of Shc-mediated transduction. 12 Overall, Shc proteins have a generic architecture and are capable of interacting with a diversity of receptors and inciting unique cellular responses. Newly revealed ShcD or RaLP (Rai-like protein) shares the defining features of the Shc family including the more conserved PTB and SH2 domains, and more divergent CH1. 1, 4 This 75 kDa protein is most similar to ShcA, but is distinguished from its counterparts by unique characteristics including novel sites of tyrosine phosphorylation, (one of which binds Grb2), an expanded CH2 domain with additional proline motifs, and a non-conventional Shc PTB domain that can accommodate a histidine residue at the -5 position relative to pTyr. 4 ShcD expression was found to be restricted to the embryonic and dult mouse brain and skeletal muscle, similar to the profiles of murine ShcB and C and in contrast to ShcA, which is expressed outside the nervous system. 4 Additionally, the protein has been located in human melanomas and implicated in tumour cell metastasis. 1 Although characterization of ShcD is still in its infancy, its interaction with Muscle Specific Kinase (MuSK) has been detailed, and comprehensive spot peptide array data suggest that the PTB domain is capable of binding a number of receptor tyrosine kinases, including those expressed in the nervous system. 4, 13 In light of their overlapping expression profiles, and the previously-documented affinity of Shc family proteins for this receptor, we propose the TrkA neurotrophin receptor as an upstream binding partner for ShcD. Broadly, the Trk family of receptor tyrosine kinases is expressed in the nervous system and coordinates neuronal response to the local environment by binding extracellular neurotrophin ligands that signal responses including survival, differentiation, and growth. 3, 5 TrkA binds Nerve Growth Factor (NGF) and is specifically involved in the fate of sympathetic and sensory neurons that deal with temperature and pain. 10 The involvement of Shc A, B, and C in potentiating the neurotrophin signal has been clearly demonstrated, and is mediated through binding of the Shc PTB domain 9, 12 to a phosphorylated tyrosine at position 490 on TrkA (Figure 2) . 3, 11 Our investigations have revealed that ShcD associates with TrkA, in a manner that is at least partially dependent on TrkA Tyr 490, and can involve both PTB and SH2 domains of ShcD. This is in contrast to the PTB domain dependence observed for the TrkA interaction with other Shc proteins, and could indicate novel functionality in neural signal transduction cascades.
MATERIALS AND METHODS

Vectors
Wildtype and modified constructs of the human TrkA receptor were obtained in pLNCX retroviral vector (Clontech) from D. Kaplan's lab and assessed via sequencing. Common primers flanking the pLNCX multiple cloning site were used to determine approximately 600 bases at the 5'and 3' termini; internal primers were then developed to sequence the intervening nucleotides. The identity of wild type TrkA was confirmed via a BLASTx database search. Mutant sequences were aligned with wild type using the SerialCloner application to detect residue modifications in the Y490F and K538A variants. Human ShcD (Accession BC033907) cDNA constructs were previously cloned into pcDNA3 (Invitrogen) with carboxy-terminal triple FLAG tags. 4 Cell culture, transfection, and protein harvesting HEK 293 cells were grown at 37 ºC in 100 mm x 20 mm cell culture dishes in 10 ml Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum and 1% penicillin / streptomycin. Plasmid transfection was performed approximately 24 hours after cell passaging by introducing 12 µg of vector DNA in 25 µl polyethyleneimine and 750 µl FBS-free medium. Experimental, positive, and negative control cultures were co-transfected with two constructs of interest, while treatment controls were either singly transfected or not transfected.
Cells were lysed on ice 46 to 48 hours post-transfection in 500 -800 µl PLC plus buffer freshly prepared with protease inhibitors (50 mM HEPES [pH 7.5], 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl 2 , 1 mM EGTA, 10 mM sodium pyrophosphate, 100 mM sodium fluoride, supplemented with 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin, and 10 µg/ml leupeptin) and centrifuged at 13 000 rpm, 4 ºC to recover protein in the whole cell lysate.
Immunoprecipitation (IP)
Fractions of lysate (250 µl to 720 µl, context-dependent) were rotated overnight at 4ºC in an 800 µl volume of primary anti-FLAG mouse monoclonal antibody (0.5 µl), 10% antimouse bead-conjugated secondary antibody (80 µl), and PLC plus buffer. (See Table 1 for a list of antibodies.) IPs were centrifuged for 1 minute at 3000 rpm to pellet beads, and aspirated to remove supernatant. Two rounds of washing with 500 µl PLC buffer, centrifugation, and aspiration were performed. Complete removal of supernatant from pellet was attempted following the final wash. 20 µl of 2 x SDS protein sample buffer was added to samples and incubated at 100 ºC for 5 minutes prior to loading.
Immunoblotting (IB)
8 µl to 10 µl of immunoprecipitated protein fractions and 13 µl whole cell lysate were electrophoresed on 8% sodium dodecyl sulfate polyacrylamide gels and transferred to PVDF membranes (Millipore) (500 mA for 30 minutes on a BioRad semi-dry transfer cell.) Phosphotyrosine blots were blocked in 5 ml 5% BSA in TBST; all others blocked in 5 mL 5% skim milk powder in TBST for a minimum of 1 hour at room temperature. Primary antibodies at 1:1000 dilution were incubated with the membranes at 4 ºC with rocking for 24 to 70 hours. Blots were washed 3 times for 10 minutes each in TBST following treatment with primary and secondary antibodies. Membranes were incubated with Horseradish peroxidase conjugated secondary antibodies (Biorad) for 1-2 hours prior to visualization with ECL chemiluminescent detection reagent (Amersham).
Membrane stripping and reblotting
ECL-treated membranes were stripped of primary and secondary antibody and re-probed for a different protein component. Stripping solution (3.5 ml water, 312 µl 1 M Tris, pH 7.5, 1 ml 10% SDS, 140 µl β-mercaptoethanol) was incubated with the membrane in a 55 ºC water bath for 30 minutes, with agitation every 5 minutes. Membranes were washed in TBST 3 times for 10 minutes each, and blocked and re-probed with antibody as previously described.
RESULTS
TrkA is phosphorylated in HEK 293 cells and occurs in two forms. The HEK 293 cell line was selected as a robust expression system to test the interactions between two introduced proteins. In physiological cell lines, endogenous TrkA requires neurotrophin stimulation to induce receptor activation, phosphorylation of cytoplasmic tyrosine residues, and binding to downstream transduction partners. 5 To assay the status of TrkA when overexpressed in non-neural cells, we introduced three human TrkA cDNA variants in pLNCX vectors to HEK 293 cells: 1) wild type TrkA, 2) a tyrosineto-phenylalanine amino acid substitution in the juxtamembrane region of the receptor that prevents phosphorylation at this residue (Y490F), and 3) a lysine-toalanine modification that incapacitates the Trk kinase catalytic domain ("kinase defective", KD), thus preventing Trk from phosphorylating itself or other targets (K538A). A cell lysate that was immunoprecipitated with Trk antibody and subsequently western blotted with the same immunoglobulin revealed a doublet corresponding to approximately 128 and 115 kDa ( Figure 3A ). TrkA is known to manifest as two bands, resulting from different levels of glycosylation. 9 Leoni et. al. have demonstrated this to be a consequence of TrkA overexpression, whereby an incompletely-glycosylated 110 kDa receptor becomes lodged in intracellular compartments. 8 Another documented outcome of TrkA overexpression in PC12 cells is constitutive activation of the receptor, as conferred by phosphorylation of its cytoplasmic domain. 8 We sought to test this in unstimulated HEK 293 cells by immunoblotting the Trk-precipitated samples with antiphosphotyrosine antibody ( Figure 3B ). This yielded a doublet pattern identical in size to that observed in Figure  3A , confirming that TrkA phosphorylation is ligandindependent in HEK 293 cells. It has been proposed that the density of receptors in an overexpression system is sufficient to induce their oligomerization and activation. 8 The level of phosphorylation detected on the western blot decreased only slightly between wildtype TrkA and the Y490F variant ( Figure 3B) . Indeed, Y490 is only one of ten evolutionarily conserved tyrosine residues that become phosphorylated in response to receptor activation. 3 As the residue is not required for regulation of the protein kinase, substitution of non-phosphorylatable phenylalanine in its place was predicted to have minimal effect on the overall phosphorylation status of TrkA.
Phosphorylation of the kinase defective TrkA variant was initially perplexing; however, subsequent DNA sequencing revealed that the desired K538A mutation was not present in the construct. TrkA wild type and Y490F cDNA sequences were confirmed to be accurate (data not shown), and these two cDNAs were used in the remainder of experiments.
ShcD binds TrkA -To determine whether human TrkA and
ShcD proteins were capable of interacting in vivo, we cotransfected HEK 293 cells with vectors containing cDNAs encoding both proteins. As shown in Figure 4 , immunoprecipitation with FLAG antibodies followed by anti-Trk immunoblotting revealed that wild type TrkA was precipitated along with the FLAG-tagged ShcD. This suggests that an interaction between the receptor and the immuno-targeted adaptor protein allowed their simultaneous recovery, providing the first cell-based evidence of their binding ability.
ShcD is phosphorylated when associated with TrkA -
Recruitment of Shc proteins to activated receptor tyrosine kinases is known to facilitate phosphorylation of three tyrosine residues in the central CH1 domain of Shc. 4, 12 In addition to these conserved motifs, ShcD has been found to contain three novel tyrosine residues that also serve as kinase substrates. 4 The phosphorylation status of ShcD was thus assessed when the protein was expressed alone or in conjunction with TrkA neurotrophin receptor in HEK 293 cells. Immunoprecipitation of FLAG-ShcD followed by a phosphotyrosine western blot revealed that when ShcD and TrkA were co-transfected, species characteristic of the TrkA doublet and ShcD singlet were phosphorylated ( Figure 5A) . The same pattern was observed in the full lysate of the cotransfected cells. In contrast, when ShcD was expressed in the absence of the TrkA receptor, it did not appear on the phosphotyrosine blot (Figure 5A) , although it was clearly present in the sample (Figure 5C ). This suggests that the ShcD protein is not tyrosine phosphorylated in isolation, but can become so in the presence of the activated Trk receptor.
TrkA itself was confirmed to be phosphorylated in the presence or absence of ShcD, and is thus not reliant on the adaptor molecule for its activation.
Binding of ShcD to TrkA is impeded by a substitution at the
TrkA tyrosine 490 -The TrkA tyrosine 490 residue is documented as the principal site of interaction between Shc proteins and the receptor, 3, 11 providing the classic NPXY motif (with Ile at the -5 position relative to Tyr) specific for Shc PTB domain. 15 The significance of this residue in mediating attachment to ShcD was investigated by co- transfecting HEK 293 cells with wildtype ShcD and a TrkA variant in which tyrosine 490 was substituted with phenylalanine, a structurally similar amino acid that lacks the phosphorylatable hydroxyl functional group. Binding of these proteins was assessed by co-immunoprecipitation and anti-Trk western blot, which revealed a marked decrease in interaction between ShcD and TrkA Y490F as compared to the association between wildtype proteins (Figure 6 ). This suggests that tyrosine 490 is influential in binding ShcD, similar to the results previously obtained for Shc A, B, and C.
Truncated, PTB domain-containing ShcD protein binds
TrkA -Upon receptor activation, Shc proteins can bind via their PTB or SH2 domains, each of which recognizes different target consensus sequences. 12 It has previously been demonstrated that the Trk/Shc interaction is entirely a function of the Shc PTB domain. 9 Although characterization of ShcD is still in its infancy, peptide array data suggest that the PTB domain binds Trk at the juxtamembrane NPXY motif. 13 To test the ability of ShcD PTB to bind TrkA, wild type receptor was co-expressed with a ShcD mutant containing only the PTB domain and the N-terminal CH2 domain, and lacking the C-terminal SH2 domain. Immunoprecipitation and immunoblotting revealed that the CH2-PTB portion of the ShcD molecule interacts with TrkA, given its ability to co-precipitate the receptor (Figure  7) . ShcD is therefore similar to other Shc proteins in which the PTB domain is sufficient to facilitate interaction with Trk. This also suggests that the N-terminal portion of ShcD functions as an autonomous, independently-folded unit of the protein that can assume an active conformation in the absence of the CH1 and SH2, as neither of these domains were required to mediate binding.
The ShcD SH2 domain strongly influences TrkA binding -
To continue investigating the domain specificity of the ShcD/TrkA interaction, two variants of the full length ShcD protein were employed. Both the PTB and SH2 domains contain a critical arginine residue in the pY binding pocket that exerts considerable control over the activity of the domain. Substituting an alternative amino acid for Arg at position 315 (PTB*) or 549 (SH2*) impedes the capacity of the respective domains to engage with the substrate. 4 These full-length proteins with single mutations were co-expressed with wild type TrkA in HEK 293 cells, and were assessed via immunoprecipitation and immunoblotting for their ability to bind the receptor. Surprisingly, we found no difference in TrkA interaction between wild type ShcD and the PTB* mutant (Figure 8, panel I, A) .
There was, however, a marked decrease in the amount of TrkA co-precipitated by the SH2* mutant, as compared to wild type and PTB* forms of ShcD. A third ShcD variant, with mutations in both the PTB and SH2 domains (PTB*/SH2*) demonstrated a TrkA binding profile identical to the SH2* protein, indicating that the additional loss of PTB functionality did not change the protein's affiliation with TrkA. Meanwhile, expression levels of ShcD and TrkA were shown to be equivalent across samples (Figure 8 panel  I, B, C) , and thus could not account for the discrepancy in TrkA co-precipitation in (A). Taken alone, these results suggest that the ShcD SH2 domain exerts a pronounced effect on TrkA binding, and may be chiefly responsible for localizing the ShcD adaptor to the neurotrophin receptor. This was an unexpected finding, considering that the associations between Shc A, B, and C and the Trk receptor are documented as occurring through their PTB domains.
We next sought to verify these previous findings by employing similarly point-substituted ShcA PTB* and SH2* variants, and evaluating their ability to bind TrkA. As shown (Figure 8, panel II) , when ShcA and TrkA were equally expressed across samples, only mutation in the ShcA PTB domain was capable of decreasing the amount of coprecipitated TrkA, while the SH2* mutation had no apparent effect on receptor binding, thus confirming published results. Clearly, the PTB and SH2 domains of ShcD and ShcA do not function equivalently in facilitating the TrkA interaction. 
DISCUSSION
The objective of this study was to determine whether the adaptor protein ShcD could serve as a downstream partner for the TrkA neurotrophin receptor tyrosine kinase, and then subsequently map the domains and residues through which they bind. Here we provide the first evidence of in vivo association between TrkA and ShcD, occurring when human cDNA constructs were transiently co-expressed in a eukaryotic cell system.
Using co-immunoprecipitation and immunoblotting, we have identified several features of the TrkA/ShcD interaction that are consistent with the behavior of other documented Shc proteins, specifically the TrkA-dependent phosphorylation of ShcD, the importance of TrkA Tyr 490 in mediating the interaction, and the capacity of the ShcD PTB domain to orchestrate the association between proteins. Our findings also reveal atypical binding characteristics, including previously undocumented influence from the ShcD SH2 domain, which position the ShcD adaptor as a novel TrkA binding partner.
Tyrosine motifs of the Shc CH1 domain were previously found to couple active receptors to downstream signaling components like Grb2, owing to their selective phosphorylation once Shc is recruited to the signaling complex. 12 Our analyses of the phosphorylation status of both TrkA and ShcD reveal that ShcD is tyrosine phosphorylated in the presence, but not in the absence, of phosphorylated TrkA. Targeted ShcD phosphorylation could thus allow the protein to act as a signal-specific adaptor that only facilitates development of the signaling complex in 
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Vol. 2, No. 1, Fall 2008, 59-70 response to stimuli that are transduced via ShcD-compatible receptors, such as TrkA. From a generic phosphotyrosine immunoblot, it is not possible to discern which of the six conserved tyrosine residues in ShcD are phosphorylated as a consequence of the protein's interaction with Trk. Development of phosphospecific antibodies against the individual motifs would allow the phosphorylation profile to be determined and compared against those induced by interaction with other receptors. This type of investigation would be particularly relevant if conducted in cell lines native to TrkA and ShcD, as they would more accurately model the signaling effects of Nerve Growth Factor on ShcD activation. Indeed, the significance of the additional tyrosine residues in ShcD as compared to Shc A, B, and C, has yet to be determined, but is currently under review by our laboratory.
TrkA tyrosine 490, the canonical point of contact between Shc proteins and the Trk receptor, is demonstrated here to fulfill a similar role in TrkA/ShcA binding. Replacement of this residue with phenylalanine substantially reduces, but does not entirely preclude, interaction between the proteins. This residual binding appears to be typical of Shc interaction experiments in which only a single residue of the target motif is substituted; it has been found to occur upon mutation of the presumptive binding sites for rat ShcB on TrkA, and for ShcD on MuSK. 9, 4 Since the PTB and SH2 domains of Shc recognize both phosphorylated tyrosine residue and the adjacent amino acids, a more drastic mutation in the binding motif is possibly required to prevent the interaction. Alternatively, continued binding in the absence of Y490 may indicate that additional sites of interaction are present within TrkA. Complete abrogation of the TrkA / Shc association has been found to result when the receptor contains a kinase-inactivating mutation, which prevents it from autophosphorylating tyrosine residues in its cytoplasmic region. 9 Our attempt to perform an analogous investigation to determine the requirements of ShcD for phosphorylated residues has not been successful, owing to a faulty TrkA "kinase dead" construct. Since overexpression of the receptor in HEK 293 cells stimulates auto-dimerization and phosphorylation, we have been unable to assess the TrkA/ShcD interaction when TrkA is in an inactive state. This remains a subject of further scrutiny.
It is also worthy of note that under the current experimental model, we cannot disregard the possibility that 
(RTK: receptor tyrosine kinase)
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Vol. 2, No. 1, Fall 2008, 59-70 a third component, found in HEK 293 cells and capable of binding both ShcD and TrkA, could be bridging their interaction. An acellular peptide binding assay, in which the presumptive motifs are immobilized and incubated with purified, epitope-tagged binding domains, 13 could distinguish between the direct and indirect protein interactions that arise in the complex environment of the cell. Shifting attention to regions of the ShcD protein that participate in TrkA binding, we find that the N-terminal half of the ShcD molecule, consisting of the CH2 and PTB domains, is independently capable of binding TrkA. Our lab is currently developing a cDNA construct of the CH1-SH2 portion of ShcD that will be used to assess the TrkA binding capacity of the adaptor C-terminus. It is documented, however, that Shc A, B, and C associate with TrkA via their PTB domains. 9 This fact, coupled with the observation that the CH2 domain contains no known mechanism to localize to, or interact with, a membrane receptor, leads us to propose that the Trk binding observed with our ShcD CH2-PTB fragment is due to the PTB domain. This could be confirmed by an in vitro GST pulldown assay in which purified, isolated, GST-fused PTB domain is incubated with TrkAcontaining lysate in the presence of glutathione-conjugated beads.
Surprisingly, further in vivo tests of domain specificity using full-length ShcD protein mutated within the PTB (PTB*) or SH2 (SH2*) domains show that disrupting the PTB domain alone has minimal consequence on the TrkA binding capacity of the protein. In contrast, the equivalent substitution in the SH2 domain drastically reduces overall TrkA affiliation. The PTB and SH2 domains of ShcD have been found to exhibit some co-operativity in binding the receptors MuSK 4 and Ret (unpublished), however, the consequences of ShcD PTB* and SH2* domain mutations on the interactions do not follow the patterns observed here. To this end, at least four models can be proposed to account for the various binding profiles of a multi domain adaptor protein, Shc, and an activated receptor tyrosine kinase.
The most straightforward interaction is described by the single domain binding model (Figure 9) , which postulates that only one domain mediates the receptor interaction, and predicts that inactivating this domain should preclude the association, while mutating other independent regions of the protein should have no effect. This type of interaction is believed to be responsible for recruiting Shc proteins (excluding ShcD) to TrkA. 9 We have confirmed that ShcA affiliation with TrkA is markedly decreased in the presence of a disabling substitution in the PTB domain, but is not affected by mutation of the SH2 domain. Though this model would also appear to explain the results of the ShcD PTB* and SH2* mutational analyses, in which alterations to the SH2 domain exclusively affect the ability of ShcD to coprecipitate TrkA, experiments with the isolated CH2-PTB region of ShcD reveal that it is also capable of binding Trk. A suitable explanation must take both of these observations into account.
A second type of interaction, which we term the independent binding model, holds that if both the PTB and SH2 domains have equal binding capacity and autonomously associate with the receptor, both would need to be concurrently disrupted to prevent the interaction (Figure 10 ). This appears to be the situation with ShcD binding to receptors MuSK and Ret, both of which require tandem ShcD PTB*/SH2* mutations to inhibit their association. 4 Surprisingly though, the isolated ShcD SH2 domain is unable to precipitate these receptors in GST pulldown assays, 4 indicating that there are additional factors influencing these interactions.
The sequential binding model considers the possible effects of adaptor activation on its interaction with the receptor (Figure 11) . It postulates that one domain (the dominant or primary domain) is responsible for localizing the protein to the receptor and initiating the association. This preliminary binding and activation would then allow the secondary domain to bind, which may provide supplementary stability to the interaction, assist the adaptor in assuming an active conformation, or otherwise influence the signal transduction process. This model is supported by recent findings revealing that, in fact, the activity of the ShcA SH2 domain is controlled by phosphorylation of tyrosine residues in the CH1 domain, which occurs when the adaptor binds to an activated receptor. 2 Due to the sequential nature of the proposed process, it is expected that a loss of function mutation in the primary domain would abolish the interaction, since the influence of the secondary domain only takes effect after initiation by the dominant domain.
Mutating the secondary domain should not affect the interaction, except to decrease its affinity. However, there would potentially be consequences on the downstream signals that emanate from this complex. In practice, it is not possible to distinguish between the single domain and sequential binding models using the co-immunoprecipitation approach. In both circumstances, the interaction would appear entirely dependent on the primary domain, since its inactivation would prevent initial contact between the proteins, and thus preclude binding. A test of the dissociation constant, K d , of the binding pair, in the presence and absence of the secondary domain might establish whether the domain was contributing additional stability. To address the question of possible signaling consequences of the secondary domain, a comprehensive study examining the downstream effects of mutated motifs on both the receptor and adaptor could also be employed. These types of investigations would be particularly pertinent to the ShcA/TrkA interaction, to discern the relevance of the SH2 domain once the adaptor has bound TrkA via its PTB domain. The ShcD /TrkA binding profile, however, does not fit the predictions of this model.
In order to assimilate our various observations about the TrkA/ShcD interaction, we propose a fourth and final paradigm, which we designate the inhibitor relief model (Figure 12) . This holds that both domains of the adaptor can independently bind the receptor, however, a single unbound domain can inhibit the other and therefore prevent binding of the entire molecule. This concept is founded on the possibility that the PTB and SH2 domains have additional functionality beyond coordinating phosphorylated tyrosine residues. In particular, it requires that one or more domains of the adaptor protein, when not bound to a target consensus sequence, could impede the function of the protein as a whole (henceforth referred to as the binding-and-repressor or BR domain). Indeed, the notion of individual domains operating as fully autonomous modules is gradually being reevaluated, as new evidence arises regarding the influence of other Shc regions on its SH2 domain. 2 Predictions made under our model suggest that mutations in the "binding-only" domain will not inhibit the interaction, since a second independent domain is still capable of facilitating the association. However, a mutation in a BR domain that prevents it from interacting with the activated receptor (but does not change the gross overall architecture of the domain) will allow it to constitutively repress the remaining functional regions of the protein, thus attenuating the receptor interaction. The model also projects that both wild type domains, in the absence of the other, should bind the activated receptor. This is precisely the pattern of interaction that we detect between ShcD and TrkA. Specifically, mutation of the ShcD PTB domain does not reduce overall binding of Trk, evidently because another region of the protein is equally capable of facilitating the interaction. In contrast, the reciprocal relationship does not hold when the SH2 domain sustains mutation, as the wild type PTB domain of the SH2* protein is unable to rescue the Trk-binding phenotype, despite its ability to associate with TrkA in the absence of the SH2 domain. It thus appears that the ShcD PTB domain functions as the "binding only" module of the model, while SH2 acts as a binding-andrepressor or BR domain. Notably, the SH2* mutation tested here is a single arginine substitution, which disrupts only the phosphotyrosine binding pocket and should not perturb the overall domain architecture, which we speculate allows the SH2 domain to continue in its "inactivated" role as a repressor of PTB. Consistent with the model, we find that complete removal the SH2 domain entirely restores the ability of ShcD to bind TrkA. We are presently awaiting development of an isolated ShcD CH1-SH2 construct to confirm whether the SH2 domain binds TrkA independently of the PTB domain. Currently, this inhibitor relief model is the best explanation of our observations.
What could be the biological significance of such a mechanism? One possibility is that it helps to prevent spurious receptor localization of ShcD in the absence of a signal, by requiring the adaptor to co-ordinate not one but two phosphorylated tyrosine residues. In this autoinhibitory fashion, the BR domain would potentate an all-or-nothing response from ShcD, precluding its association with a partially active or spuriously phosphorylated receptor.
Our focus thus far has been on the physical associations between ShcD and TrkA that mediate their interaction. However, understanding the role of this molecular complex in cellular and organismal development, maintenance, and pathology is the ultimate goal.
In tissues that express Shc and Trk proteins endogenously, these signal transducers exist in intricate webs of association that define cellular responses such as survival, proliferation, and differentiation through major pathways that include Ras/MAPK and PI-3K. 5, 11 The specific consequence of wild type TrkA-ShcD signaling on cultured neurons can 
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Vol. 2, No. 1, Fall 2008, 59-70 be assessed by overexpressing Shc protein in PC12 cells of rat pheochromocytoma origin, as described by Liu and Meakin. 9 Following neurotrophin stimulation, select pathway constituents can be recovered and analyzed for their level of activation relative to nontransfected, stimulated cells. Likewise, any changes in morphology such as differentiation and neurite outgrowth that arise from ShcD upregulation and cellular treatment with nerve growth factor (NGF) can be observed. Subsequent to this work, we propose a ShcD "up/down" system to determine the roles of the individual ShcD domains in potentiating the NGF signal. This could be accomplished by introducing one of our ShcD variant proteins (such as the CH2-PTB truncation) into PC12 cells, while simultaneously eliminating the confounding endogenous wildtype ShcD using antisense RNA complementary to a region of the protein not present in the transfected species. Analyzing downstream signaling that occurs in response to NGF stimulation would indicate the significance of the introduced protein region. A key question arising from recent studies is the relevance of the Shc SH2 domain in signaling. As depicted in our sequential binding and inhibitor relief models of adaptor activation, the SH2 domain potentially has several functions in the protein, and it remains to be seen whether Shc can transduce signals normally when it lacks only the SH2 domain. This topic is especially provocative considering that the functionally important tyrosine motifs known to facilitate Grb2 binding (and hence couple Shc to downstream effectors) are all located in the central CH1 domain. Perhaps the SH2 domain represents a hitherto unexplored transduction component of the Shc protein, capable of selectively interacting with additional effectors and coupling the activated receptor to a further repertoire of signaling possibilities. This in turn may begin to explain how signaling differs between Shc adaptors.
Indeed, one of the great conundrums facing modern cell biology is the question of specificity arising from apparent uniformity, a concept exemplified by Trk-Shc signaling. It is documented that the three receptor tyrosine kinases of the Trk family display neurotrophin specificity, with TrkA binding to NGF, Trk B to BDNF and NT-4/5, and TrkC to NT-3. 10 It is also widely reported that these receptors can differ markedly in the types of cell effects that they potentiate, and that a given receptor can have different consequences in different tissues. 3 A striking example of this occurs in the case of neuroblastoma tumor cells, in which TrkA is a good prognostic marker and functions to induce apoptosis, while TrkB induces survival and proliferation of the tumour. 7 Given the distinct roles that the different receptors adopt, the discovery that ShcA, B, and C all bind TrkA, B, and C, and do so via the same phosphorylated Trk residue, 9 appears contraindicative to the specificity with which these signaling cascades operate. In addition, Shc proteins are said to be functionally nonredundant, 1 contributing differently to development. 9 While removal of two critical exons in the mouse ShcA gene results in embryonic lethality by E11.5, 6 ShcB -/-ShcC -/double knockouts lose a portion of their superior cervical ganglia neurons. 9 The consequence of ShcD loss to the organism is currently under investigation by our lab. Clearly, a major intellectual task in the field of Shc signaling involves reconciling a model in which Shc adaptors are distinct, yet widely employed, and appear to propagate unique signals through shared mechanisms. 
